A UK collaboration bringing together world-leading experts in stem cell biology, physiology and health economics is advancing a first-in-class regenerative therapy for Hirschsprung disease. This horizon-scanning feature highlights its potential to reshape gastrointestinal care for affected children.
Hirschsprung disease is a congenital disorder of the gastrointestinal tract characterised by the absence of ganglion cells, particularly in the distal colon and rectum. These cells form part of the complex enteric nervous system, which regulates gut motility, secretion and coordination of digestion.
When this system fails to develop properly during embryogenesis, the affected bowel segment cannot relax or propagate peristalsis, leading to obstruction and progressive dilation of the upstream intestine.
Clinically, the disease typically presents in the neonatal period, with hallmark features including failure to pass meconium within the first 48 hours of life, abdominal distension and vomiting.
In less severe cases, symptoms may manifest later in childhood as chronic constipation, poor growth and recurrent abdominal pain. The condition can also lead to serious complications such as intestinal perforation, enterocolitis and sepsis, which remain major causes of morbidity and mortality.
Current management is centred on surgery, and while this approach dramatically improves survival and addresses the anatomical defect, it does not address the underlying neurodevelopmental pathology.
Many patients therefore continue to experience long-term gastrointestinal dysfunction, including obstructive symptoms, faecal incontinence and recurrent enterocolitis, which can significantly impair quality of life into adulthood.
Regenerative therapies for Hirschsprung disease
As interest grows in regenerative, stem cell-based strategies to repopulate the bowel and restore normal gut motility, researchers from Queen’s University Belfast (QUB), the University of Sheffield and University College London (UCL) Great Ormond Street Institute of Child Health are developing a novel therapy aiming to address the root cause of Hirschsprung disease. This signals a shift from symptomatic management towards disease-modifying treatment and targeting a critical unmet need.
The £2.7m UK Research and Innovation-funded project has already produced promising early results. Researchers from the University of Sheffield have developed a method to grow the missing nerve cells from human stem cells in just six days – nearly twice as fast as previous techniques.
These lab-grown cells have been shown to integrate into human tissue and restore the rhythmic contractions required for normal gut function. Crucially, they can be produced as an ‘off-the-shelf therapy’, meaning they can be stored, transported and delivered across healthcare systems.
Dr Anestis Tsakiridis, who leads the programme at the University of Sheffield and is a senior lecturer at the School of Biosciences, emphasised the translational ambition of the work, describing the funding as ‘a unique opportunity to move the therapy one step closer to the clinic’.
Bridging science and clinical care
Clinical translation is central to the collaboration, with teams working closely to ensure the therapy is viable in real-world settings.
Dr Conor McCann, associate professor in paediatric regenerative medicine and principal investigator at UCL Great Ormond Street Institute of Child Health, highlighted the clinical significance of the project, saying: ‘We hope that by bringing together the expertise of different groups across the UK we can drive this project towards a clinical trial that will hopefully benefit children with Hirschsprung disease and their families.’
Alongside biological development, the project is also addressing how the therapy could be implemented within the NHS, with ongoing research by Dr Felicity Lamrock, senior lecturer in data analytics at QUB, and UCL collaborators, examining a health economic framework to assess cost-effectiveness and support future adoption.
‘Generating early economic evidence will be key to supporting the assessment of its value for money as it progresses towards clinical adoption within the NHS,’ she says.
A potential paradigm shift for Hirschsprung disease
If successful, the stem cell therapy could offer a one-off, disease-modifying treatment, replacing repeated surgeries with a regenerative solution. Early modelling suggests it may also be cost-effective, reducing the long-term burden on healthcare systems and families.
The research teams also believe that beyond Hirschsprung disease, the platform could have broader applications for other gastrointestinal disorders involving nerve dysfunction, such as gastroparesis and achalasia.
While clinical trials remain a future step, the collaboration represents a significant advance in translating stem cell science into tangible patient benefits.